Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 7
Submit an article Journal homepage
86
Views
5
CrossRef citations to date
0
Altmetric
Review

Controversies in breast cancer: adjuvant and neoadjuvant therapy

Filippo Montemurro Institute for Cancer Research and Treatment, Unit of Medical Oncology, IRCC Candiolo, Strada Provinciale 142,10060 Candiolo, Torino, Italy. [email protected]
,
Stefania Redana Institute for Cancer Research and Treatment, Unit of Medical Oncology, IRCC Candiolo, Strada Provinciale 142,10060 Candiolo, Torino, Italy. [email protected]
,
Giorgio Valabrega Institute for Cancer Research and Treatment, Unit of Medical Oncology, IRCC Candiolo, Strada Provinciale 142,10060 Candiolo, Torino, Italy. [email protected]
&
Massimo Aglietta Institute for Cancer Research and Treatment, Unit of Medical Oncology, IRCC Candiolo, Strada Provinciale 142,10060 Candiolo, Torino, Italy. [email protected]
Pages 1055-1072 | Published online: 15 Jun 2005

Bibliography

  • PARKIN DM, BRAY F, FERLAY J et ell.: Global cancer statistics, 2002. CA Cancer]. Clin. (2005) 55:74–108.
  • KARRISON TG, FERGUSON DJ, METER P: Dormancy of mammary carcinoma after mastectomy. J. NatL Cancer Inst. (1999) 91:80–85.
  • DEMICHELI R, TERENZIANI M, VALAGUSSA P et al.: Local recurrences following mastectomy: support for the concept of tumor dormancy. J. NatL Cancer Inst. (1994) 86:45–48.
  • ELLIS MJ, HAYES DF, LIPPMAN ME: Treatment of metastatic breast cancer. In: Diseases of the Breast (3rd Edition). JR Harris, ME Lippman, M Morrow, CK Osborne. Lippincott Williams & Wilkins, Philadelphia, PA, USA (2004):101–1117.
  • EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 352:930–942.
  • ••A meta-analysis of randomised trials ofadjuvant chemotherapy involving several thousands of women with operable breast cancer.
  • EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (1998) 351:1451–1467.
  • ••A meta-analysis of randomised trials ofadjuvant endocrine therapy with tamoxifen involving — 37,000 women in 55 clinical trials.
  • FISHER B, JEONG JH, ANDERSON S et al.: Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from national surgical adjuvant breast and bowel project clinical trials. J. NatL Cancer Inst. (2004) 96:1823–1831.
  • BONADONNA G, VALAGUSSA P, MOLITERNI A et al.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N EngL J. Med. (1995) 332:901–906.
  • BONADONNA G, BRUSAMOLINO E, VALAGUSSA P et al.: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N EngL J. Med. (1976) 294:405–410.
  • FISHER B, REDMOND C, DIMITROV NV et aL: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl. J. Med. (1989) 320:473–478.
  • EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Effects of adjuvant chemotherapy and hormonal therapy on breast cancer recurrence and long-term survival. Lancet (In press).
  • NABHOLTZ JM, TONKIN K, SMYLIE M et al.: Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert. Opin. Pharmacother. (2000) 1:187–206.
  • NOWAK AK, WILCKEN NR, STOCKLER MR et al.: Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol (2004) 5:372–380.
  • HENDERSON IC, BERRY DA, DEMETRI GD et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol (2003) 21:976–983.
  • ••The first randomised trial of adjuvantchemotherapy showing that DFS and OS were improved by the addition of paclitaxel in women with LN-positive operable breast cancer.
  • MAMOUNAS EP, BRYANT J, LEMBERSKY C et al.: Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc. Am. Soc. Clin. Oncol (2003) 22:4 (Abstract 12).
  • MARTIN M, PIENKOWSKI T, MACKEY J et al.: TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. 26th Annual San Antonio Breast Cancer Symposium (2003). Abstract 43.
  • ROCHE H, FUMOLEAU P, SPIELMANN M et al.: Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):S16 (Abstract 27).
  • NORTON L: Conceptual basis for advances in the systemic drug therapy of breast cancer. Semin. Oncol (1997) 24:S11–S12.
  • CITRON ML, BERRY DA, CIRRINCIONE C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol (2003) 21:1431–1439.
  • ••This randomised trial provided evidence ofsuperiority of dose-dense regimens, compared with conventionally scheduled anthracydine-taxane-based adjuvant chemotherapy.
  • LOESCH D, GRECO FA, O'SHAUGHNESSY J et al.: A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res. Treat. (2004) 88\(Suppl. 1):S16 (Abstract 28).
  • MC/BUS VJ, UNTCH M, DU BOIS A et al.: Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (>= 4 +LN). First results of an AGO-trial. Proc. Am. Soc. Clin. Oncol (2004) 22:14s–513.
  • FISHER B, DIGNAM J, BRYANT J et al.: Five wrsus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. J. Natl Cancer Inst. (2001) 93:684–690.
  • ALBAIN K, BARLOW W, O'MALLEY F et al.: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). 27th Annual San Antonio Breast Cancer Symposium (2004). Abstract 37.
  • RING A, DOWSETT M: Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer (2004) 11:643–658.
  • NABHOLTZ JM, REESE D: Anastrozole in the management of breast cancer. Expert. Opin. Pharmacother. (2002) 3:1329–1339.
  • DIXON JM: Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert. Opin. Pharmacother. (2004) 5:307–316.
  • BAUM M, BUDZAR AU, CUZICK J et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359:2131–2139.
  • ••A randomised trial involving 9000postmenopausal women, showing that anastrozole resulted in superior DFS, compared with tamoxifen.
  • BAUM M, BUZDAR A, CUZICK J et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer (2003) 98:1802–1810.
  • HOWELL A. CUZICK J, BAUM M et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet (2005) 365:60–62.
  • GOSS PE, INGLE JN, MARTINO S et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl. J. Med. (2003) 349:1793–1802.
  • ••The continuation of letrozole after thecompletion of 5 years with tamoxifen resulted in increased DFS. The study was prematurely closed for a striking superiority of letrozole compared with placebo.
  • GOSS PE, INGLE JN, MARTINO S et al.: Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc. Am. Soc. Clin. Oncol. (2004) 22:88s–847.
  • BOCCARDO F, RUBAGOTTI A, AMOROSO D et al.: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res. Treat. (2003) 82 (Suppl. 1):56 (Abstract 3).
  • COOMBES RC, HALL E, GIBSON LJ et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl. J. Med. (2004) 350:1081–1092.
  • ••Switching to exemestane after 2 years ofadjuvant endocrine therapy with tamoxifen results in improved DFS in post-menopausal women with endocrine sensitive breast cancer.
  • JAKESZ R, KAUFMANN M, GNANT M et al.: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res. Treat. (2004) 88\(Suppl. 11):S7 (Abstract 2).
  • ••Switching to anastrozole after 2 years ofadjuvant endocrine therapy with tamoxifen results in improved DFS in post-menopausal women with endocrine sensitive breast cancer.
  • BIG 1–98 COLLABORATIVE GROUP: BIG 1–98: A prospective randomized double-blind double-dummy Phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast (2005) 14\(Suppl. 1):53 (Abstract S4).
  • ••This randomised trial showed that upfrontadjuvant endocrine therapy with letrozole for 5 years is superior to 5 years with tamoxifen in terms of DFS in women with endocrine-sensitive operable breast cancer.
  • DOWSETT M, SMITH I: Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res. Treat. (2003) 82\(Suppl. 1):S7 (Abstract 4).
  • NICHOLSON RI, HUTCHESON IR, KNOWLDEN JM et al.: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin. Cancer Res. (2004) 10:346S–354S.
  • •A very intriguing paper reviewing potential mechanisms of resistance to endocrine agents used in the treatment of breast cancer.
  • WINER EP, HUDIS C, BURSTEIN HJ et al.: American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.1 Clin. Oncol (2005) 23:619–629.
  • MINTON SE, MUNSTER PN: Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control (2002) 9:466–472.
  • PROWELL TM, DAVIDSON NE: What is the role of ovarian ablation in the management of primary and metastatic breast cancer noclay? Oncologist (2004) 9:507–517.
  • EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet (1996) 348:1189–1196.
  • ••A metanalysis including - 3400 pre-menopausal women with operable breast cancer enrolled in randomised trials of ovarian function suppression.
  • JONAT W, KAUFMANN M, SAUERBREI Wet al.: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol (2002) 20:4628–4635.
  • Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet (1993) 341:1293–1298.
  • SCHMID P, UNTCH M, WALLWIENER D et al.: Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study with Leuprorelin Acetate). Anticancer Res. (2002) 22:2325–2332.
  • EJLERTSEN B, DOMBERNOWSKY P, MOURIDSEN H et al.: Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc. Am. Soc. Clin. Oncol (1999) 18:66a (Abstract 248).
  • THURLIMANN B, PRICE K, GELBER RD et al.: Endocrine therapy alone with ovarian function suppression polus tamoxifen, versus endocrine therapy plus chemotherapy: is chemotherapy usefull for premenopausal women, with node-positive, endocrine responsive breast cancer? First results of IBCSG trial 11–93. Breast (2001) 10\(Suppl. 1):10S (Abstract).
  • ARRIAGADA R, LE MG, SPIELMANN M et al.: Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann. Oncol (2005) 16(3):389–396.
  • DAVIDSON NE, O'NEILL A, VUKOV A et al.: Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188,INT-0101). Proc. Am. Soc. Clin. Oncol (2003) 22:5. (Abstract 15).
  • CASTIGLIONE-GERTSCH M, O'NEILL A, PRICE KN et al.: Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. 1 Natl Cancer Inst. (2003) 95:1833–1846.
  • BOCCARDO F, RUBAGOTTI A, AMOROSO D et al.: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. Clin. Oncol (2000) 18:2718–2727.
  • ROCHE H, KERBRAT P, BONNETERRE J et al.: Complete Hormonal blockade wrsus chemotherapy in premenopausal early-stage breast cancer patients (Pts) with positive hormone-receptor (HR+) and 1–3 node-positive (N+) tumor: results of the FASG 06 trial. Proc. Am. Soc. Clin. Oncol (2000) 19:72a. (Abstract 279).
  • ROCHE H, MIHURA J, DE LAFONTAN B et al.: Castration and tamoxifen versus chemotherapy (FAC) for premenopausal node and receptor positive breast cancer patients: a randomised trial with a 7 years median follow-up. Proc. Am. Soc. Clin. Oncol (1996) 15:117 (Abstract)
  • JAKESZ R, HAUSMANINGER H, KUBISTA E et al.: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. (2002) 20:4621–4627.
  • WOLFF AC, DAVIDSON NE: Primary systemic therapy in operable breast cancer. J. Clin. Oncol. (2000) 18:1558–1569.
  • KAUFMANN M, VON MINCKWITZ G, SMITH R et al.: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J. Clin. Oncol (2003) 21:2600–2608.
  • HORTOBAGYI GN, SINGLETARY SE, STROM EA: Locally advanced breast cancer. In: Diseases of the Breast (3rd Edition). JR Harris, ME Lippman, M Morrow, CK Osborne. Lippincott Williams & Wilkins, Philadelphia, PA, USA (2004):951–969.
  • FISHER B, SAFFER E, RUDDOCK C et al.: Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res. (1989) 49:2002–2004.
  • FISHER B, GUNDUZ N, COYLE J et al.:Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. (1989) 49:1996–2001.
  • FISHER B, GUNDUZ N, SAFFER EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. (1983) 43:1488–1492.
  • MAURI D, PAVLIDIS N, IOANNIDIS JPA: Neoadjuvant versus systemic treatment in breast cancer: a meta-analysis. J. Natl. Cancer Inst. (2005) 97:188–194.
  • FISHER B, BRYANT J, WOLMARK N et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol (1998) 16:2672–2685.
  • ••The first large randomised trial comparingadjuvant with neoadjuvant anthracydine-based chemotherapy for operable breast cancer. The study showed that the two arms had equal OS rates.
  • WOLMARK N, WANG J, MAMOUNAS E et al.: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monogr. (200 I ): 96–102.
  • BUCHHOLZ TA, HUNT KK, WHITMAN GJ et al.: Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer (2003) 98:1150–1160.
  • GOGAS H, FOUNTZILAS G: The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Ann. Oncol (2003) 14:667–674.
  • SMITH IC, HEYS SD, HUTCHEON AW et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol (2002) 20:1456-1466. HUTCHEON AW, HEYS SD, SARKAR TK et al.: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res. Treat. (2003) 82\(Suppl. 1):59 (Abstract 11). The results of this trial showed that adding docetaxel to women showing chemosensitivity to anthracydine-containing neoadjuvant therapy improved DFS and OS.
  • BEAR HD, ANDERSON S, BROWN A et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol (2003) 21:4165–4174.
  • BEAR HD, ANDERSON S, SMIT RE et al.: A randomized trial comparing preoperative (preop) doxorubicin/ cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) Tin patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. (2004) 88\(Suppl. 11):S16 (Abstract 26).
  • ••This study showed that, despite apathological complete remission rate that was doubled by the addition of preoperative docetaxel to AC compared with AC alone, OS was not influenced by the preoperative or postoperative addition of docetaxel.
  • EIERMANN W, SABADELL D, BASELGA J et al.: European cooperative trial in operable breast cancer (ECTO): no increased risk of local breast tumor recurrence (LBR) as first and only event after primary systemic therapy (PST). Proc. Am. Soc. Clin. Oncol (2003) 22:10 (Abstract 37).
  • VON MINCKWITZ G, BLOHMER JU, RAAB G et al.: In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann. Oncol (2005) 16:56–63.
  • CHANG JC, WOOTEN EC, TSIMELZON A et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 362:362–369.
  • EIERMANN W, PAEPKE S, APPFELSTAEDT J et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol (2001) 12:1527–1532.
  • MILLER WR, DIXON JM: Endocrine andclinical endpoints of exemestane as neoadjuvant therapy. Cancer Control (2002) 9:9–15.
  • ELLIS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-I- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Clin. Oncol. (2001) 19:3808–3816.
  • DIXON JM, RENSHAW L, BELLAMY C et al.: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res. (2000) 6:2229–2235.
  • SMITH I, DOWSETT M: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res. Treat. (2003) 82\(Suppl. 1):56. (Abstract 1).
  • DOWSETT M, EBBS SR, DIXON JM et al.: Biomarker changes during neoadjuvant anastrozole, lamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J. Clin. Oncol (2005) 23(11):2477–2492.
  • SEMIGLAZOV VF, SEMIGLAZOV V, IVANOV Vet al.: The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. Proc. Am. Soc. Clin. Oncol (2004) 22:7s–519.
  • MONTEMURRO F, UENO NT, RONDON G et al: High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin. Breast Cancer (2000) 1:197–209.
  • PETERS WP, ROSNER GL, VREDENBURGH JJ et al.: Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.J. Clin. Oncol (2005) 23(10):2191–2200.
  • HORTOBAGYI GN, BUZDAR AU, THIERAULT RL et al.: Randomized trial of high-dose chemotherapyand blood cells autografts for high-risk primary carcinoma. J. Natl. Cancer Inst. (2000) 92:225–233.
  • BERGH J, WIKLUND T, ERIKSTEIN B et al.: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet (2000) 356:1384–1391.
  • CROWN JP, LIND M, GOULD A et al: High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary nodes (4+LN): the Anglo-Celtic 1 study. Proc. Am. Soc. Clin. Oncol (2002) 21:166.
  • GIANNI A, BONADONNA G: Five-year results of the randomized clinical trial comparing standard wrsus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with 3 positive nodes (LN+). Proc. Am. Soc. Clin. Oncol (2001) 20:21a. (Abstract 80).
  • RODENHUIS S, BONTENBAL M, BEEX LV et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl. J. Med. (2003) 349:7–16.
  • TALLMAN MS, GRAY R, ROBERT NJ et al.: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl. J. Med. (2003) 349:17–26.
  • ZANDER AR, KROGER N, SCHMOOR C et al: High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J. Clin. Oncol. (2004) 22:2273–2283.
  • NITZ U, FRICK M, MOHRMANN S et al.: Tandem high dose chemotherapy versus dose-dense conventional chemotherapy for patients with high risk breast cancer: Interim results from a multicenter phase III trial. Proc. Am. Soc. Clin. Oncol (2003) 22:832. (Abstract 3344).
  • WEISS RB, RIFKIN RM, STEWART FM et al.: High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet (2000) 355:999–1003.
  • MONTEMURRO F, VALABREGA G, AGLIETTA M: Trastuzumab-based combination therapy for breast cancer. Expert Opin. Phormacother. (2004) 5:81–96.
  • SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl. J. Med. (2001) 344:783–792.
  • GEYER CE, BRYANT J, ROMOND E et al.: Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). Breast Cancer Res. Treat. (2003) 82\(Suppl. 1):513. (Abstract 23).
  • MONTEMURRO F, AGLIETTA M: Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin. Breast Cancer (In Press).
  • BUZDAR AU, IBRAHIM NK, FRANCIS D et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol E-pub ahead of print.
  • ••This randomised study was stoppedprematurely because of a striking superiority of the trastuzumab-containing arm in terms of pathological complete remission rate.
  • DIAB SG, ELLEDGE RM, CLARK GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl Cancer Inst. (2000) 92:550–556.
  • EXTERMANN M, BALDUCCI L, LYMAN GH: What threshold for adjuvant therapy in older breast cancer patients? Clin. Oncol (2000) 18:1709–1717.
  • BALDUCCI L: Geriatric Oncology. Crit. Rev. Oncol HematoL (2003) 46:211–220.
  • BALDUCCI L, EXTERMANN M: Management of cancer in the older person: a practical approach. Oncologist (2000) 5:224–237.
  • GREENHALGH T: How to read a paper: statistics for the non-statistician. II: 'significant' relations and their pitfalls. Br. Med. J. (1997) 315:422–425.
  • SHAPIRO CL, RECHT k Side effects of adjuvant treatment of breast cancer. /V.MONTEMURROEng/ J. Med. (2001) 344:1997–2008.
  • CUFER T, PICCART-GEBHART M: Adjuvant chemotherapy: standards and beyond. Breast (2005) 14\(Suppl. 1):53 (Abstract S6).
  • BONETTI M, GELBER RD: A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat. Med. (2000) 19:2595–2609.
  • VAN DE VIJVER M, HE YD, VAN'T VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl. J. Med. (2002) 347:1999–2009.
  • ••A milestone in the field of new prognosticand predictive systems.
  • PAIK S, SHAK S, TANG G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl. J. Med. (2004) 351:2817–2826.
  • PICCART MJ, LOI S, VAN'T VEER LJ et al: Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? 27th Annual San Antonio Breast Cancer Symposium (2004). (Abstract 38). Websites

Websites

  • http://www.asco.org ROMOND EH, PEREZ EA, BYANT J et al.: Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for HER-2 positive operable breast cancer: combined analysis of NSABP-B31/NCCTG-N9831. Presented at the 2005 annual meeting of the American Society of Clinical Oncology, Orlando, FL, USA (2005).
  • http://www.asco.org PEREZ EA, SUMAN VJ, DAVIDSON N et al.: NCCTG N9831: May 2005 update. Presented at the 2005 annual meeting of the American Society of Clinical Oncology Orlando FL, USA (2005).
  • http://www.asco.org PICCART-GEBHART MJ, ON BEHALF OF THE BREAST INTERNATIONAL GROUP (BIG) N-BpgisFH-LRL: First Results of the HERA Trial. Presented at the 2005 annual meeting of the American Society of Clinical Oncology, Orlando FL, USA (2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.